Suite C301, P.O. Box 28<br>Research Institute of T
High-Tech Park, Nanshan District
8 articles with Chipscreen Biosciences
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Chipscreen Biosciences Co., Ltd. and Novogene Co., Ltd. recently announced a strategic partnership for companion diagnostics development.
Chipscreen Biosciences Announces a Collaboration with Innovent to Evaluate Chidamide and the Combination of Sintilimab, Anti-VEGF Monoclonal Antibody IBI305 in Colorectal Cancer patients
Chipscreen Biosciences announce the signing of a collaboration agreement with Innovent Biologics, Inc. to evaluate the safety and tolerability of Chipscreen's Chidamide and Innovent's Sintilimab in combination with an anti-VEGF monoclonal antibody IBI305 in patients with advanced colorectal carcinoma.
Chipscreen Biosciences Out-Licenses Taiwanese Rights for Cancer Drug to GNT Biotech and Medicals Corporation
Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
Chipscreen Biosciences and HUYA Bioscience International Announce Promising Preclincial and Phase I Solid Tumor/Lymphoma Data for Chidamide/HBI-8000